Search Results
Your search for Patricia A. Ganz, MD matches 14 pages
Showing 1 - 14
Patricia A. Ganz, MD, on Early Breast Cancer, Olaparib, Chemotherapy, and Quality of Life
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses quality-of-life results from the phase III OlympiA study of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract GS4-09).
Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related symptoms such as fatigue and sleep disturbance, which pose serious threats to younger women’s...
Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation
Patricia A. Ganz, MD, of NRG Oncology and Jonsson Comprehensive Cancer Center at UCLA, discusses the NRG/NSABP phase III findings, which showed that partial-breast irradiation was more convenient and resulted in less fatigue but slightly poorer cosmesis at 36 months in patients who did not receive...
Patricia A. Ganz, MD: Aromatase Inhibitors Data Review
Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).
Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer
A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...
Adjuvant Endocrine Therapy for Primary Breast Cancer Treatment Associated With Increased Symptom Burden Over 12 Months
Patients in the observational Mind-Body Study receiving adjuvant endocrine therapy for primary breast cancer treatment reported a greater symptom burden than did patients not receiving endocrine therapy over 12 months, as reported by Ganz et al in the Journal of Clinical Oncology. No differences in ...
Patient-Reported Outcomes With Adjuvant Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
As reported in The Lancet and at the recent San Antonio Breast Cancer Symposium, Ganz et al found differences in patient-reported outcomes with anastrozole vs tamoxifen in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial in postmenopausal women with hormone...
Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
SABCS 2015: Patients With Ductal Carcinoma in Situ Receiving Anastrozole Reported Symptoms Different From Those in Patients Receiving Tamoxifen
Analysis of patient-reported outcomes, a secondary endpoint of the phase III NSABP B-35 clinical trial, in which anastrozole and tamoxifen were compared in postmenopausal women with ductal carcinoma in situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in...
Study Questions Cost-Effectiveness of Universal BRCA Screening
Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who do not have the mutations. A viewpoint published recently in JAMA Oncology by researchers at the University of California Los Angeles questioned...
New Study Reveals Effective Treatment Program for Breast Cancer Survivors With ‘Chemobrain’
In a new study, UCLA researchers have developed a cognitive rehabilitation program to address post-treatment cognitive changes, sometimes known as “chemobrain,” which can affect up to 35% of post-treatment breast cancer patients. Their findings were reported by Erocli et al in...
Language and Communication Cognitive Complaints Worsen After Initiation of Endocrine Therapy in Early-Stage Breast Cancer
Data suggest that cancer treatment puts patients at risk of cognitive impairment and that many patients exhibit impairment prior to treatment. In an observational cohort study reported in the Journal of Clinical Oncology, Ganz et al found that language and communication cognitive complaints were...
ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer
Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...
ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing
Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...
